Latest tweet from our researchers:

Holland P, Hagopian WM, Jahren AH, Rusten TE (2021)
Natural abundance isotope ratios to differentiate sources of carbon used during tumor growth in vivo
BMC Biol, 19 (1), 85
DOI 10.1186/s12915-021-01012-5, PubMed 33966633

Sioud M (2021)
Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
EBioMedicine, 67, 103351
DOI 10.1016/j.ebiom.2021.103351, PubMed 33965875

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer
DOI 10.1002/ijc.33672, PubMed 33961700

Fløisand Y, Schroeder MA, Chevallier P, Selleslag D, Devine S, Renteria AS, Mohty M, Yakoub-Agha I, Chen C, Parfionovas A, Quadri S, Jansson J, Akbari M, Chen YB (2021)
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease
Bone Marrow Transplant
DOI 10.1038/s41409-021-01356-0, PubMed 34108672

Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K (2021)
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
JCI Insight, 6 (11)
DOI 10.1172/jci.insight.147617, PubMed 33886505

Rudolph MJ, Poon AY, Kavaliauskiene S, Grethe Myrann A, Reynolds-Peterson C, Davis SA, Sandvig K, Vance DJ, Mantis NJ (2021)
Structural analysis of toxin-neutralizing, single-domain antibodies that bridge ricin's A-B subunit interface
J Mol Biol, 167086 (in press)
DOI 10.1016/j.jmb.2021.167086, PubMed 34089718